PTO/SB/06a (05-07)
Approved for use through 09/09/207 OMS 0851-0231
U.S. Patenti and Trademark Office, U.S. DEPARTMENT OF COMMERCE It os collection of information unless it contrars a valid OMS control number. Under the Paperwork Reduction Act of 1995, no persons are requir

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT
STATEMENT BY APPLICANT
(Not for submission under 37 CFR 1.99)
,

Application Number		10505224
Filing Date		2004-08-20
First Named Inventor Yoshi		inori Teshima
Art Unit		2628
Examiner Name Danie		C Washburn
Attorney Docket Number		ASAIN0150

				Auditiey Doc	ACC HUITIDES	AUAII VOI 30				
				U.S.	PATENTS			Remove		_
Examiner Initial*			entee or Applicant ument	Releva		ines where es or Relev				
	1	5095419		1992-03-10	Seki et al.					
	2	6504742		2003-01-07	Tran et al.					
If you wis	h to a	dd additional U.S. Pate	nt citatio	n information p	lease click the	Add button.		Add		_
			U.S.P	ATENT APPLI	CATION PUB	LICATIONS		Remove		_
Examiner Initial*	Cite No	Publication Number	Kind Code ¹	Publication Date	Name of Pat of cited Doc	entee or Applicant ument	Releva	Columns,L int Passage s Appear	ines where es or Relev	an
If you wis	Ė	dd additional U.S. Publ	ished Ap	plication citatio			d button	Add		_
Examiner Initial*	Cite No	Foreign Document Number ³	Countr Code ²		Publication Date	Name of Patente Applicant of cited Document	e or	vhere Rele	r Relevant	Ψ,
	1									
					1					
If you wis	h to a	dd additional Foreign P	atent Do	cument citation	information p	lease click the Add	button	Add		

Application Number 10505224 Filing Date 2004-08-20 INFORMATION DISCLOSURE First Named Inventor Yoshinori Teshima STATEMENT BY APPLICANT Art I Init 2628 (Not for submission under 37 CFR 1.99) Evaminor Namo Daniel C Washburn Attorney Docket Number ASAIN0150

Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item

T5

(book, magazine, journal, serial, symposium, catalog, etc), date, pages(s), volume-issue number(s),

	1	OKAMOTO, Katsunari et al., "Stress Analysis of Optical Fibers by a Finite Element Method," October 1961, IEEE Vol QE-17, No. 10, pp. 2123-2129,	
	2	Office Action issued in related application no. 10/482,919, dated June 29, 2007.	

If you wish to add additional non-patent literature document citation information please click the Add button

Date Considered Examiner Signature

publisher, city and/or country where published.

EXAMINER SIGNATURE *EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 See Kind Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. 2 Enter office that issued the document, by the two-letter code (WIPO Standard ST.3). 3 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. 5 Applicant is to place a check mark here if English language translation is attached.

Examiner Cite

Initials* No.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)

Application Number		10505224	
Filing Date		2004-08-20	
First Named Inventor	Yoshinori Teshima		
Art Unit		2628	
Examiner Name	Danie	d C Washburn	
Attorney Docket Number		ASAIN0150	

CERTIFICATION STATEMENT

Please see 37	CFR 1.97	and 1.98 to	make the appro	priate selection(s):
---------------	----------	-------------	----------------	----------------------

That each item of information contained in the information disclosure statement was first cited in any communication from a foreign patient office in a counterpart foreign application not more than three months prior to the filing of the information disclosure statement. Sea 37 CFF 1.37(e)(1).

OR

That no item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing the certification after making reasonable inquiry, no item of information contained in the information disclosure statement was known to any involved designated in 37 CFR 156(c) more than three months prior to the filing of the information disclosure statement. See 37 CFR 157(s)(s).

- See attached certification statement.
- Fee set forth in 37 CFR 1.17 (p) has been submitted herewith.
- _ ...

SIGNATURE

A signature of the applicant or representative is required in accordance with CFR 1.33, 10.18. Please see CFR 1.4(d) for the form of the signature.

Signature	/Joerg-Uwe Szipl/	Date (YYYY-MM-DD)	2007-07-25
Name/Print	Joern-Live Szini	Registration Number	31799

This collection of information is required by 3T CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file fand by the USPTO to process) an application. Confidentially is governed by \$5 U.S. C. 12 and 37 CFR 1.14. This collection is estimated to take 1 hour to complete, including gathering, preparing and submitting the completed application from the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete his form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. operament of Commence, P. 0. Box 1445, Alexandria, V.S. 2315-1450, D. ONT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, V.S. 2313-1450.

Privacy Act Statement

The Privacy Act of 1974 (P.L. 93-579) requires that you be given certain information in connection with your submission of the stacked form related to a petient application or patient. Accordingly, pursuant to the requirements of the Act, please be advised that (1) the general authority for the collection of this information is 35 U.S.C. 2(b)(2); (2) familishing of the information solicided is civulating; and (3) the principal purpuse for which the information is used by the U.S. Patient and Trademan Coffice is to process and/or cosmisting your submission related to a patient agricultant or patient. If you do not furnish the requested process and/or cosmisting your submission related to a patient agricultant or patient. If you do not furnish the requested process and the process of the process and the process of the pro

The information provided by you in this form will be subject to the following routine uses:

- The information on this form will be treated confidentially to the extent allowed under the Freedom of Information Act (5 U.S.C. 552) and the Privacy Act (5 U.S.C. 552a). Records from this system of records may be disclosed to the Department of Justice to determine whether the Freedom of Information Act requires disclosure of these records.
 - A record from this system of records may be disclosed, as a routine use, in the course of presenting evidence to a court, magistrate, or administrative tribunal, including disclosures to opposing counsel in the course of settlement negotiations.
 - A record in this system of records may be disclosed, as a routine use, to a Member of Congress submitting a request involving an individual, to whom the record perfains, when the individual has requested assistance from the Member with respect to the subject matter of the record.
 - A record in this system of records may be disclosed, as a routine use, to a contractor of the Agency having need for the information in order to perform a contract. Recipients of information shall be required to comply with the requirements of the Privacy Act of 1974, as amended, pursuant to 5 U.S.C. 552(m).
 - A record related to an International Application filed under the Patent Cooperation Treaty in this system of records
 may be disclosed, as a routine use, to the International Bureau of the World Intellectual Property Organization, pursuant
 to the Patent Cooperation Treaty.
 - A record in this system of records may be disclosed, as a routine use, to another federal agency for purposes of National Security review (35 U.S.C. 181) and for review pursuant to the Atomic Energy Act (42 U.S.C. 218(c)).
 - 7. A record from this system of records may be disclosed, as a routine use, to the Administrator, General Services, or hisher designed, uturing an insection of records conducted by GSA as part of that agency's responsibility to recommend improvements in records management practices and programs, under authority of 4d U.S.C. 2904 and 2905. Such disclosure shall be made in accordance with the GSA requisions governing inseption of records for this purpose, and any other relevant (i.e., GSA or Commerce) directive. Such disclosure shall not be used to make determinations about individuals.
- A record from this system of records may be disclosed, as a routine use, to the public after either publication of the
 application pursuant to 35 U.S.C. 12(2) or issuance of a patent pursuant to 35 U.S.C. 151. Further, a record may be
 disclosed, subject to the limitations of 37 CFR 1.14, as a routine use, to the public if the record was filled in application
 which became abandoned or in which the proceedings were terminated and which application is referenced by either a
 published application, an application open to public inspections or as issued patent.
 - A record from this system of records may be disclosed, as a routine use, to a Federal, State, or local law enforcement agency, if the USPTO becomes aware of a violation or potential violation of law or regulation.